Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(8):1265–1270. doi: 10.1038/sj/bjc.6690496

Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases

J Walls 1, A Assiri 2, A Howell 3, E Rogers 1, W A Ratcliffe 4, R Eastell 2, N J Bundred 1
PMCID: PMC2362370  PMID: 10376982

Abstract

Objective assessment of response in bone metastases from breast cancer using radiological techniques takes up to 6 months of treatment to be certain of a response, and sclerotic metastases are not evaluable. Standard serum and urinary tumour markers may not always be utilized to predict response, as they may not be elevated, and therefore may not change on treatment. The development of the urinary pyridinoline cross-link assays which measure mature bone breakdown products have been shown to be highly sensitive and specific as a measure of bone change in osteoporosis. We have measured pyridinoline (Pyr) and deoxypyridinoline (Dpyr) cross-links sequentially in 36 breast cancer patients with bone metastases, to determine if the measurement of these analytes predicts response at an earlier stage than radiological assessment. Response was assessed by UICC criteria. Seventeen women responded to hormonal therapy, whilst 19 developed progressive disease. Both Pyr and Dpyr increased sequentially in women with progressive disease with changes becoming apparent by 8 weeks (P < 0.03). In responding women, cross-link levels did not change significantly. Pyr and Dpyr were more sensitive and specific than the standard serum tumour marker CA 15-3. Urinary cross-link measurements provide a novel objective method of assessing response to treatment in women with bone metastases. Initial elevated urinary cross-link markers identify patients who tend not to respond to changes in hormonal therapy. © 1999 Cancer Research Campaign

Keywords: breast cancer, pyridinoline cross-links, bone metastases

Full Text

The Full Text of this article is available as a PDF (96.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bettica P., Moro L., Robins S. P., Taylor A. K., Talbot J., Singer F. R., Baylink D. J. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem. 1992 Nov;38(11):2313–2318. [PubMed] [Google Scholar]
  2. Coleman R. E., Houston S., James I., Rodger A., Rubens R. D., Leonard R. C., Ford J. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992 May;65(5):766–768. doi: 10.1038/bjc.1992.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987 Jan;55(1):61–66. doi: 10.1038/bjc.1987.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coleman R. E., Whitaker K. B., Moss D. W., Mashiter G., Fogelman I., Rubens R. D. Biochemical prediction of response of bone metastases to treatment. Br J Cancer. 1988 Aug;58(2):205–210. doi: 10.1038/bjc.1988.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colwell A., Russell R. G., Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest. 1993 Jun;23(6):341–349. doi: 10.1111/j.1365-2362.1993.tb02034.x. [DOI] [PubMed] [Google Scholar]
  6. Delmas P. D., Schlemmer A., Gineyts E., Riis B., Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 1991 Jun;6(6):639–644. doi: 10.1002/jbmr.5650060615. [DOI] [PubMed] [Google Scholar]
  7. Eastell R., Colwell A., Hampton L., Reeve J. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res. 1997 Jan;12(1):59–65. doi: 10.1359/jbmr.1997.12.1.59. [DOI] [PubMed] [Google Scholar]
  8. Eyre D. New biomarkers of bone resorption. J Clin Endocrinol Metab. 1992 Mar;74(3):470A–470C. doi: 10.1210/jcem.74.3.1740477. [DOI] [PubMed] [Google Scholar]
  9. Fujimoto D. Evidence for natural existence of pyridinoline crosslink in collagen. Biochem Biophys Res Commun. 1980 Apr 14;93(3):948–953. doi: 10.1016/0006-291x(80)91167-5. [DOI] [PubMed] [Google Scholar]
  10. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  11. Moro L., Gazzarrini C., Crivellari D., Galligioni E., Talamini R., de Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem. 1993 Jan;39(1):131–134. [PubMed] [Google Scholar]
  12. Mundy G. R., Ibbotson K. J., D'Souza S. M. Tumor products and the hypercalcemia of malignancy. J Clin Invest. 1985 Aug;76(2):391–394. doi: 10.1172/JCI111984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Paterson C. R., Robins S. P., Horobin J. M., Preece P. E., Cuschieri A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer. 1991 Nov;64(5):884–886. doi: 10.1038/bjc.1991.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
  15. Ratcliffe W. A., Hutchesson A. C., Bundred N. J., Ratcliffe J. G. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet. 1992 Jan 18;339(8786):164–167. doi: 10.1016/0140-6736(92)90220-w. [DOI] [PubMed] [Google Scholar]
  16. Robertson J. F., Pearson D., Price M. R., Selby C., Blamey R. W., Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer. 1991 Oct;64(4):757–763. doi: 10.1038/bjc.1991.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Robertson J. F., Willsher P. C., Cheung K. L., Blamey R. W. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer. 1997 Oct;33(11):1774–1779. doi: 10.1016/s0959-8049(97)00178-0. [DOI] [PubMed] [Google Scholar]
  18. Sano M., Kushida K., Takahashi M., Ohishi T., Kawana K., Okada M., Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994 Oct;70(4):701–703. doi: 10.1038/bjc.1994.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wada S., Katayama Y., Yasutomo Y., Kugai N., Nagata N. Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Intern Med. 1993 Aug;32(8):611–618. doi: 10.2169/internalmedicine.32.611. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES